Merus to Present at the 2018 Wedbush PacGrow Healthcare Conference
UTRECHT, The Netherlands, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President and Chief Business Officer, will present a company overview at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018, at 12:45 p.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl . An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Additional pipeline programs include MCLA-117, which is currently being studied in a Phase 1 clinical trial in patients with acute myeloid leukemia, and MCLA-158, a Biclonics® being studied in a Phase 1 clinical trial in patients with solid tumors with an initial focus on metastatic colorectal cancer. Through its collaboration with Incyte Corporation, Merus is also developing a preclinical bispecific antibody designed to bind to PD-L1 and a non-disclosed second immunomodulatory target. For additional information, please visit Merus’ website, www.merus.nl.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Collibra23.5.2019 15:01:20 CEST | Pressemeddelelse
Collibra Announces 2019 Excellence Awards Winners
XBiotech Inc.23.5.2019 14:21:06 CEST | Pressemeddelelse
XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa
Merus N.V.23.5.2019 14:02:11 CEST | Pressemeddelelse
Merus Announces 2019 Annual General Meeting of Shareholders
YPO23.5.2019 09:01:35 CEST | Pressemeddelelse
YPO Global Pulse Survey Finds the Customer is Always Right
Euro Manganese Inc.22.5.2019 23:11:07 CEST | Pressemeddelelse
Euro Manganese Provides Operational Update for the Chvaletice Manganese Project
Tricentis22.5.2019 17:03:19 CEST | Pressemeddelelse
Tricentis Disrupts RPA Market with Resilient Model-Based Automation
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum